David W. Nassif

CIK 1636975 · CFO / CLO · last filed 2026-05-26

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$3.70M

Companies

4

Total Filings

15

Lifetime Open-Market Net

-$402.8K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PHVS CFO / CLO 120,300 $30.72 $3.70M -$303.1K 1 2026-05-26
Sio Gene Therapies Inc. (SIOX) Delisted Interim CEO, CFO 51,538 $0.48 $24.6K $0 4 2022-02-10
Sio Gene Therapies Inc. (AXGT) Delisted Principal Financial Officer 18,944 $0 4 2020-06-15
SteadyMed Ltd. (STDY) Delisted EVP and CFO 22,157 -$99.7K 5 2018-07-09

Recent Filings · Page 2 of 2

15 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2018-07-09 SteadyMed Ltd. (STDY) Delisted Sell (S) −12,157 -$54.7K EDGAR
2018-07-03 SteadyMed Ltd. (STDY) Delisted Sell (S) −10,001 -$45.0K EDGAR
2017-12-28 SteadyMed Ltd. (STDY) Delisted Grant (A) $0 EDGAR
2017-11-15 SteadyMed Ltd. (STDY) Delisted Grant (A) +44,315 $0 EDGAR
2016-07-22 SteadyMed Ltd. (STDY) Delisted Grant (A) $0 EDGAR
Showing 1115 of 15
Page 2 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.